Remnant gastric cancer (RGC) is a rare but clinically significant malignancy that develops in the remaining part of the stomach after partial gastrectomy. In terms of diagnosis, therapy, and prognosis, it represents special difficulties. Although the precise cause of RGC is still unknown, several factors have been identified as potential risk factors, including Helicobacter pylori infection, prior gastric surgery, postoperative complications, and patient-related factors. Recent studies have given insight into certain genetic mutations, chromosomal abnormalities, and molecular pathways related to the pathogenesis of RGC, which involves complex molecular modifications. Despite improvements in diagnostic methods, including molecular markers and imaging modalities, RGC is frequently identified at an advanced stage with a bad prognosis. Multidisciplinary collaboration and further research efforts are necessary to improve our understanding of RGC and develop effective management strategies to enhance patient outcomes.